Haemonetics Stock Reaction and Recent Performance

Haemonetics (HAE) has drawn fresh attention after recent share price moves, with the stock up 2.5% over the past week and 3.5% over the past month, while the past 3 months show a 14.6% decline.

Looking beyond the recent bounce, Haemonetics has a 1 year total shareholder return of 7.78% but a 3 year total shareholder return decline of 27.78%, while the share price is currently at $61.62 and year to date momentum has been weak. This suggests recent strength is more of a short term recovery than a clear trend shift.

If you are assessing how health focused names are trading around shifting sentiment, this could be a useful moment to widen your watchlist with 35 healthcare AI stocks

With Haemonetics trading at $61.62, alongside an indicated intrinsic discount of about 32% and analyst targets implying additional upside, the key question is simple: is this genuine value, or is the market already pricing in future growth?

Preferred Price-to-Earnings of 16.3x: Is It Justified?

On the numbers provided, Haemonetics trades on a P/E of 16.3x, while the last close is $61.62 and multiple indicators suggest the market may be pricing the shares below several reference points.

The P/E ratio simply compares the current share price to earnings per share, so a lower P/E can imply the market is assigning a lower value to each dollar of earnings. For a medical technology business that is already profitable, P/E is a common yardstick investors use when comparing opportunities within the same sector.

Here, Haemonetics screens as good value relative to both peers and the broader US Medical Equipment industry. Its 16.3x P/E sits well under the peer average of 27.6x and the industry average of 25.8x. It also sits below an estimated fair P/E of 21.5x. This points to a level the market could potentially move toward if earnings quality, growth and risk are viewed more in line with that fair ratio benchmark.

Result: Price-to-Earnings of 16.3x (UNDERVALUED)

However, there are clear risks, including future pressure on Haemonetics’ 5.2% revenue growth rate and any shift in market confidence given its weaker 3 and 5 year returns.

Another View: Cash Flow Signals Point To Deeper Value

While the 16.3x P/E suggests Haemonetics may be priced conservatively, the SWS DCF model points to a fair value of $90.48 per share versus the current $61.62, which implies the stock trades about 31.9% below that estimate. If both earnings and cash flow screens lean positive, what is the market still hesitant about?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Haemonetics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 59 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given this mix of cautious pricing and potential upside, it makes sense to move fast, review the full picture, and decide where you stand using the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If Haemonetics has caught your eye, do not stop here. Use this momentum to scan for other opportunities and keep your watchlist one step ahead.

• Spot potential value setups by checking companies that currently score well on quality and pricing with the 59 high quality undervalued stocks.
• Prioritize resilience by reviewing companies that pass strict balance sheet and fundamentals checks using the solid balance sheet and fundamentals stocks screener (42 results).
• Get ahead of the crowd by scanning a screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.